Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.